United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average (own scale)
Sector average (own scale)
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Ernexa Therapeutics Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
| ROE | -686.69% | 301% | 74.96% | 42.85% | 30.02% | 23.17% |
|---|---|---|---|---|---|---|
| Sector average | 20.42% | 71.17% | 5.82% | 58.79% | 17.46% | 2.74% |
| ROA | -253.7% | -292.53% | -361.54% | -361.64% | -361.96% | -363.31% |
| Total Assets | $5,834.00K | $3,950.00K | $3,950.00K | $3,950.00K | $3,950.00K | $3,950.00K |
| Sector average | $3,280,499.23K | $3,298,345.31K | $3,676,894.01K | |||
| Net Income | -$14,084.00K | -$14,310.81K | -$14,280.94K | -$14,284.66K | -$14,297.58K | -$14,350.59K |
| $4,262,561.28K |
| $4,994,412.92K |
| $5,761,557.24K |